HB 365 2013

A bill to be entitled 1 2 An act relating to pharmacy; creating s. 465.0252, 3 F.S.; providing definitions; providing requirements 4 for a pharmacist to dispense a substitute biological 5 product that is determined to be biosimilar to and 6 interchangeable for the prescribed biological product; 7 requiring the Board of Pharmacy to maintain a current 8 list of interchangeable biosimilar products; providing 9 an effective date. 10 11 Be It Enacted by the Legislature of the State of Florida: 12 13 Section 1. Section 465.0252, Florida Statutes, is created 14 to read: 15 465.0252 Substitution of interchangeable biosimilar 16 products.-(1) As used in this section, the terms "biological 17 product, " "biosimilar, " and "interchangeable" have the same 18 meanings as defined in s. 351 of the federal Public Health 19 20 Service Act, 42 U.S.C. s. 262. 21 (2) A pharmacist may only dispense a substitute biological product for the prescribed biological product if: 22 23 The United States Food and Drug Administration has

- (a) The United States Food and Drug Administration has determined that the substitute biological product is biosimilar to and interchangeable for the specified indicated use of the prescribed biological product.
- (b) The prescribing health care provider does not express a preference against substitution in writing, verbally, or

Page 1 of 2

CODING: Words stricken are deletions; words underlined are additions.

24

25

26

27

28

HB 365 2013

electronically.

- (c) The pharmacist notifies the person presenting the prescription of the substitution in the same manner as provided in s. 465.025(3)(a).
- dispensing the substitute biological product in lieu of the prescribed biological product, notifies the prescribing health care provider of the substitution by facsimile, telephone, voicemail, e-mail, electronic medical record, or other electronic means.
- (e) The pharmacist and the prescribing health care provider each retain a written record of the substitution for at least 4 years.
- (3) The board shall maintain on its public website a current list of biological products that the United States Food and Drug Administration has determined are biosimilar and interchangeable as provided in paragraph (2)(a).
  - Section 2. This act shall take effect July 1, 2013.